Baidu
map

CLIN CANCER RES:结直肠腺瘤的循环标志物

2018-05-16 MedSci MedSci原创

结直肠癌是世界范围内发病率第三的肿瘤,每年会导致700000人死亡。大部分结直肠癌良性时为腺瘤。结直肠腺瘤的检测目前往往由结肠镜完成,但是由于其较高的成本及侵入性,该检查通常局限于有家族史等高风险人群。CLIN CANCER RES近期发表了一篇文章,娅就是否可以用血液里的小RNA标志检测结直肠腺瘤。

结直肠癌是世界范围内发病率第三的肿瘤,每年会导致700000人死亡。大部分结直肠癌良性时为腺瘤。结直肠腺瘤的检测目前往往由结肠镜完成,但是由于其较高的成本及侵入性,该检查通常局限于有家族史等高风险人群。CLIN CANCER RES近期发表了一篇文章,娅就是否可以用血液里的小RNA标志检测结直肠腺瘤。

作者对189例患者的血浆进行了小RNA测序,平衡了年龄,性别和家族史因素。采用的分析方法可以同时检测到microRNA和其他小RNA。在一个独立队列中使用qPCR重复了测序结果。研究结果表明,有几个小RNA种类与结直肠腺瘤有显着关系,包括microRNA和非microRNA小RNA。这些关系在纠正了患者协变量(包括年龄)后更为明显。在腺瘤相关小RNA中,两种,miR-335-5p亚型和一种未注释的小RNA在独立队列中通过qPCR得到验证。这两种小RNA在独立队列中检测腺瘤的AUC为0.755。这一方法可以准确检测腺瘤。

文章最后认为,测序发现且qPCR验证的循环小RNA(包括但不限于miRNA)可以有效识别结直肠腺瘤患者。

原始出处:
Brain S.Roberts,Andrew A.Haardigan,et al.Discovery and Validation of Circulating Biomarkers of Colorectal Adenoma by High-Depth Small RNA Sequencing.CLIN CANCER RES.May 2018 doi:10.1158/1078-0432.CCR-17-1960

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1841235, encodeId=3b82184123546, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Feb 05 16:21:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453114, encodeId=decf1453114d6, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri May 18 09:21:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315855, encodeId=8cd3315855be, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 17 06:39:59 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315725, encodeId=fdec315e2572, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 16 19:38:16 CST 2018, time=2018-05-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1841235, encodeId=3b82184123546, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Feb 05 16:21:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453114, encodeId=decf1453114d6, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri May 18 09:21:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315855, encodeId=8cd3315855be, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 17 06:39:59 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315725, encodeId=fdec315e2572, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 16 19:38:16 CST 2018, time=2018-05-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1841235, encodeId=3b82184123546, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Feb 05 16:21:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453114, encodeId=decf1453114d6, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri May 18 09:21:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315855, encodeId=8cd3315855be, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 17 06:39:59 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315725, encodeId=fdec315e2572, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 16 19:38:16 CST 2018, time=2018-05-16, status=1, ipAttribution=)]
    2018-05-17 kafei

    学习了谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1841235, encodeId=3b82184123546, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Feb 05 16:21:00 CST 2019, time=2019-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1453114, encodeId=decf1453114d6, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Fri May 18 09:21:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315855, encodeId=8cd3315855be, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 17 06:39:59 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315725, encodeId=fdec315e2572, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed May 16 19:38:16 CST 2018, time=2018-05-16, status=1, ipAttribution=)]
    2018-05-16 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

相关资讯

GUT:阿托伐他汀和舒林酸居然可以预防结直肠腺瘤!

人群个体对一些预防性干预的反应是互不相同的。近期,一项发表在杂志GUT上的研究旨在确定化学预防剂的功效是否在非肿瘤动物与结直肠肿瘤动物中有所不同。研究者们将舒林酸(Sulindac)和/或阿托伐他汀(Atorvastatin)施用于治疗开始时具有已知肿瘤负荷状态的Apc+/Min-FCCC小鼠。此项研究中的雄性小鼠(6-8周龄)均接受结肠镜检查,并接受舒林酸(300ppm),阿托伐他汀(100pp

JNCI:虽然塞来昔布能预防结直肠腺瘤复发,但心血管毒性不容忽视

环氧化酶(COX)- 2抑制剂塞来昔布具有抗炎活性,但不能抑制COX-1。该药物可以下调COX-2,进而抑制结直肠癌的发生。 硒和塞来昔布试验(Selenium and Celecoxib)是一项随机安慰剂对照试验,参与者每日服用硒200 µg和/或塞来昔布400 mg,预防结直肠腺瘤的发生。研究纳入了40-80岁、经结肠镜检查后切除腺瘤的男女性参与者。主要结局为新发腺瘤。因其他试验发现塞来

JNCI:补充硒不能预防结直肠腺瘤,还会增加2型糖尿病风险

既往的研究表明,补充硒可能有助于预防结直肠癌;结直肠腺瘤作为结直肠癌的前体,那么补充硒能否预防结直肠腺瘤?此外,硒补充剂还可能会增加2型糖尿病风险。 Sel/Cel试验是一项随机安慰剂对照试验,每天服用硒200 µg(富硒酵母)和/或塞来昔布400 mg,作为结直肠腺瘤的预防措施。研究纳入40-80岁结肠镜下切除腺瘤的男性和女性。主要结果为腺瘤的发展。虽然在其他试验中,塞来昔布表现出了心血管

Gastroenterology:瑞金医院袁耀宗发现高膳食纤维摄入可减少结直肠腺瘤发病风险

结直肠腺瘤是癌症的先兆,对人类健康有潜在的致命性危险。关于膳食纤维摄入量和结直肠腺瘤发病风险的关系,目前尚未达成一致结论。为探究膳食纤维摄入与结直肠腺瘤的关系,上海交通大学瑞金医院消化科袁耀宗等进行了一项研究,对二者之间的关系进行了更为综合的定量分析,其结果在线发表于2013年11月8日的Gastroenterology杂志上。研究发现丰富的膳食纤维摄入可以减少结直肠腺瘤的发病风险。【原文下载】

Cancer Epidem Biomark.:二甲双胍或可降低结直肠腺瘤复发风险

现有文献表明,最常用的双胍类药物——二甲双胍或能降低结直肠癌(CRC)风险。由于大多数CRCs发病于癌前期病变腺瘤,研究人员在息肉切除术后的2型糖尿病患者中,考察了二甲双胍使用是否降低结直肠腺瘤风险。此项美国研究2015年9月发表在《Cancer Epidemiol Biomarkers Prev.》上。

SCI REP:血浆C-反应蛋白水平与结直肠腺瘤患病率的相关性分析!

总之,这项研究的结果表明肥胖相关的全身性低度炎症可能在大肠癌发生的早期阶段起着重要的作用。

Baidu
map
Baidu
map
Baidu
map